Vaxcyte Inc. (PCVX)

NASDAQ: PCVX · Real-Time Price · USD

35.43

-0.41 (-1.14%)

At close: May 01, 2025, 3:38 PM

-1.14% (1D)

Bid	35.43
Market Cap	4.56B
Revenue (ttm)	n/a
Net Income (ttm)	-463.93M
EPS (ttm)	-3.8
PE Ratio (ttm)	-9.32
Forward PE	-7.74
Analyst	Buy

Ask	35.44
Volume	3,129,249
Avg. Volume (20D)	2,028,752
Open	35.72
Previous Close	35.84
Day's Range	31.29 - 36.02
52-Week Range	27.66 - 121.06
Beta	1.26

About PCVX

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a co...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 12, 2020

Employees 414

Stock Exchange NASDAQ

Ticker Symbol PCVX

Website https://vaxcyte.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for PCVX stock is "Buy." The 12-month stock price forecast is $145, which is an increase of 309.26% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-3.67%

Shares of vaccine stocks are trading lower after C... Unlock content with Pro Subscription

4 weeks ago

-14.65%

Vaxcyte shares are trading lower after multiple firms cut their respective price targets on the stock.

News

3 weeks ago · zacks.com

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

4 weeks ago · zacks.com

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

1 month ago · seekingalpha.com

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It...

1 month ago · benzinga.com

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (P...

2 months ago · seekingalpha.com

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Con...